PRODUCTS

TCR Bispecific Antibody

Pipeline

No.
Target
Indications
TCR cloning
Affinity Optimization
Pre-clinical
Clinical Trial
CRPKVA11
Target
KRAS G12V
Indication
Colorectal & Pancreatic Cancer
 

IND in 2024

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

IND in 2024

CRPM1A2
Target
MAGE A1
Indication
Multiple tumors
 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

CRPKDA11
Target
KRAS G12D
Indication
Colorectal & Pancreatic Cancer
 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

CRPE7A2
Target
HPV16 E7
Indication
HPV16 infection, Cervical cancer
 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

CRPE7A2
Target
HBV Env
Indication
Hepatitis B
 

TCR Cloning
 
Optimization
 
Pre-clinical
 
Clinical Trial
 

Tumor indications covered by early TCR-T products

Antigen targets
under development
Covered HLA genotypes
China Han
Caucasian
Covered HLA genotypes
China Han
Caucasian

Chronic infection indications covered by early TCR Bispecific Antibody products

Chronic HPV Infection

•There has not been an effective treatment yet for the about 300 million patients worldwide, with tens of millions of patients in China

•HPV specific TCR bispecific antibody are expected to (clear infections)eliminate cells infected by HPV and cure HPV infection

Chronic HBV Infection

•Approximately 260 million patients worldwide, with 70 million in China

•Currently, the virus can only be inhibited to replicate but not eliminated

•HBV specific TCR bispecific antibody are expected to clear infections

Product Advantages

TCR Bispecific Antibody
  • Strong targeting capability that covers intracellular antigens, and 90% of cellular proteins can be used as targets
  • The clinical efficacy of TCR bispecific antibody has been verified
  • The mild CRS reactions indicate good safety
  • With lower cost and better accessibility, the drugs can be applied to more indications and first-line treatments